Special Considerations in the Management of HIV-Infected Patients From Minority Communities

  • Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
  • Section Editor: Judith S. Currier, MD, MSc
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/9/18 (What's New)

Summary

  • REALMRK trial was a single-arm study evaluating raltegravir in treatment-naive and -experienced patients, of whom 56% were black[Squires 2013b]
  • Response rates were similar for black and nonblack patients
  • Clinical adverse events considered drug related occurred in 14% of blacks and 9% of nonblacks

Action required